Upside case
Bull case
$124+88.6%
COO would need investors to value it at roughly 27x earnings — about 13x more generous than today's 14x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated Jun 18, 2026
The Cooper Companies, Inc. (COO) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
25
analysts
16 bullish · 1 bearish · 25 covering COO
Strong Buy
0
Buy
16
Hold
8
Sell
1
Strong Sell
0
Consensus Target
$80
+21.9% vs today
Scenario Range
$59 – $124
Model bear to bull value window
Coverage
25
Published analyst ratings
Valuation Context
14.2x
Forward P/E · Market cap $12.9B
COO price targets
Three scenarios for where COO stock could go
Current
~$66
Confidence
47 / 100
Updated
Jun 18, 2026
Where we are now
Current · $66
Bear
$59
Base
$94
Bull
$124
Market caseClosest to today
Base case
$94+43.1%
At 20x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$59-9.8%
If investor confidence fades or macro conditions deteriorate, a 1x multiple contraction could push COO down roughly 10% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
The Cooper Companies, Inc.
COO · NASDAQHealthcareMedical - Instruments & SuppliesOctober year-end
The Cooper Companies is a global medical device company specializing in contact lenses and women's healthcare products. It generates revenue primarily through its CooperVision segment — which sells contact lenses for various vision conditions — and its CooperSurgical segment, which offers fertility, surgical, and diagnostic products for women's health. The company's competitive advantage lies in its dual focus on vision correction and women's healthcare, creating a diversified medical device portfolio with established brands and global distribution networks.
Market Cap
$12.9B
Revenue TTM
$4.2B
Net Income TTM
$236M
Net Margin
5.6%
COO Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
83%Exceptional
12 quarters tracked
Revenue Beat Rate
67%Exceptional
vs consensus estimates
Avg EPS Surprise
+4.0%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 4 of 4Q3 2025
EPS
$1.10/$1.07
Revenue
$1.1B/$1.1B
Q4 2025
EPS
$1.15/$1.11
Revenue
$1.1B/$1.1B
Q1 2026
EPS
$1.10/$1.03
Revenue
$1.0B/$1.0B
Q2 2026
EPS
$1.21/$1.10
Revenue
$1.1B/$1.1B
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $1.10/$1.07 | +2.8% | $1.1B/$1.1B | -0.3% |
| Q4 2025 | $1.15/$1.11 | +3.6% | $1.1B/$1.1B | +0.4% |
| Q1 2026 | $1.10/$1.03 | +6.8% | $1.0B/$1.0B | +0.0% |
| Q2 2026 | $1.21/$1.10 | +10.0% | $1.1B/$1.1B | +2.6% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$4.5B
+6.7% YoY
FY2
$4.7B
+4.6% YoY
EPS Outlook
FY1
$2.35
+94.3% YoY
FY2
$2.60
+10.6% YoY
Trailing FCF (TTM)$570M
FCF Margin: 13.5%
Next Earnings
—
Expected EPS
—
Expected Revenue
—
COO beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
COO Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $4.1B
Product Mix
Latest annual revenue by segment or product family
Coopervision Segment
67.0%
+5.2% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
UNITED STATES
46.4%
+6.4% YoY
Tap, hover, or focus a slice to inspect segment detail.
Coopervision Segment is the largest disclosed segment at 67.0% of FY 2025 revenue, up 5.2% YoY.
UNITED STATES is the largest reported region at 46.4%, up 6.4% YoY.
COO Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Slightly expensive versus peers
Fair value est. $58 — implies -11.9% from today's price.
Premium to Fair Value
11.9%
above fair value
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
COO
35.2x
vs
S&P 500
24.4x
+44% premium
vs Healthcare Trailing P/E
COO
35.2x
vs
Healthcare
22.1x
+59% premium
vs COO 5Y Avg P/E
Today
35.2x
vs
5Y Average
36.1x
In line with benchmark
Forward PE
14.2x
S&P 500
18.8x
-24%
Healthcare
18.3x
-22%
5Y Avg
—
—
Trailing PE
35.2x
S&P 500
24.4x
+44%
Healthcare
22.1x
+59%
5Y Avg
36.1x
-2%
PEG Ratio
—
S&P 500
1.66x
—
Healthcare
1.59x
—
5Y Avg
—
—
EV/EBITDA
14.0x
S&P 500
15.2x
-8%
Healthcare
14.2x
-1%
5Y Avg
20.6x
-32%
Price/FCF
29.6x
S&P 500
20.7x
+43%
Healthcare
18.5x
+60%
5Y Avg
49.4x
-40%
Price/Sales
3.1x
S&P 500
3.1x
+2%
Healthcare
2.6x
+19%
5Y Avg
4.9x
-35%
Dividend Yield
—
S&P 500
1.91%
—
Healthcare
1.50%
—
5Y Avg
0.02%
—
| Metric | COO | S&P 500 | Healthcare | 5Y Avg COO |
|---|---|---|---|---|
| Forward PE | 14.2x | 18.8x-24% | 18.3x-22% | — |
| Trailing PE | 35.2x | 24.4x+44% | 22.1x+59% | 36.1x |
| PEG Ratio | — | 1.66x | 1.59x | — |
| EV/EBITDA | 14.0x | 15.2x | 14.2x | 20.6x-32% |
| Price/FCF | 29.6x | 20.7x+43% | 18.5x+60% | 49.4x-40% |
| Price/Sales | 3.1x | 3.1x | 2.6x+19% | 4.9x-35% |
| Dividend Yield | — | 1.91% | 1.50% | 0.02% |
COO trades above S&P 500 benchmarks on 2 of 5 measured multiples — is elevated on some multiples, but competitive on others — a mixed valuation picture.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolCOO Financial Health
Verdict
Adequate
COO generates $570M in free cash flow at a 13.5% margin — returns 2.3% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$4.2B
Revenue Growth
TTM vs prior year
+6.1%
Gross Margin
Gross profit as a share of revenue
64.4%
Operating Margin
Operating income divided by revenue
11.8%
Net Margin
Net income divided by revenue
5.6%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$1.21
Free Cash Flow (TTM)
Cash generation after capex
$570M
FCF Margin
FCF as share of revenue — the primary cash quality signal
13.5%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
4.8%
ROA
Return on assets, trailing twelve months
1.9%
Cash & Equivalents
Liquid assets on the balance sheet
$111M
Net Debt
Total debt minus cash
$2.7B
Debt Serviceability
Net debt as a multiple of annual free cash flow
4.7× FCF
~4.7 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
2.8%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
2.3%
Dividend
—
Buyback
2.3%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$290M
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Declining as buybacks retire shares
195M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageCOO Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 18, 2026
Medium
Leadership uncertainty
The resignation of Antalpha Platform Holding's CEO and COO created negative sentiment, potentially leading to a sell-off of COO shares.
Lower
Market sentiment
No major earnings surprises or regulatory actions emerged, but incremental catalysts drove stock movement.
High Risk
Business segment focus
The company operates in specialized medical device segments (CooperVision and CooperSurgical), which may face sector-specific risks.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why COO Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 18, 2026
Strong revenue guidance
The company has provided optimistic earnings guidance for fiscal year 2026, expecting total revenue of $4.285 billion - $4.321 billion with organic growth of 3.5% to 4.5%.
Robust financial performance
The Cooper Companies reported strong fourth-quarter and full-year 2025 results, with sales rising to $1,065.2 million and $4,092.4 million respectively, alongside positive net income and diluted EPS.
Diverse healthcare network
The company operates 130 primary and specialty care offices with 1,900 physicians and advanced practice providers, offering expert care in 95 specialties, indicating a strong and diversified healthcare presence.
Analyst optimism
Stock forecasts and analyst price target predictions for COO include detailed revenue and earnings estimates, reflecting positive sentiment from professional investors.
Real-time investor insights
Top investors provide real-time analysis on COO, including bull/bear takes, catalysts, and price targets, suggesting active interest and potential upside.
LED lighting leadership
Cooper Lighting offers an industry-leading portfolio of LED lighting and controls across residential, sports, infrastructure, industrial, and commercial sectors, positioning the company as a market leader.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
COO Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$65.91
52W Range Position
23%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$58.89
+11.9% from the low
52-Week High
$89.83
-26.6% from the high
1 Month
+8.16%
3 Month
-7.39%
YTD
-18.7%
1 Year
-5.6%
3Y CAGR
-10.6%
5Y CAGR
-7.2%
10Y CAGR
+4.8%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
COO vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
14.2x
vs 18.4x median
-23% below peer median
Revenue Growth
+6.7%
vs +6.6% median
+2% above peer median
Net Margin
5.6%
vs 13.2% median
-58% below peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
COO COO The Cooper Companies, Inc. | $12.9B | 14.2x | +6.7% | 5.6% | Buy | +21.9% |
BLC BLCO Bausch + Lomb Corporation | $5.3B | 18.4x | +6.6% | -4.2% | Hold | +24.9% |
EW EW Edwards Lifesciences Corporation | $50.4B | 29.0x | +9.8% | 17.6% | Buy | +10.5% |
HSI HSIC Henry Schein, Inc. | $9.2B | 14.9x | +5.5% | 3.0% | Buy | +9.4% |
HOL HOLX Hologic, Inc. | $17.0B | 17.2x | +4.3% | 13.2% | Hold | +3.5% |
JNJ JNJ Johnson & Johnson | $550.4B | 19.7x | +7.0% | 27.3% | Buy | +10.1% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
COO Dividend and Capital Return
COO returns 2.3% annually — null% through dividends and 2.3% through buybacks.
Dividend UnknownFCF Unknown
Total Shareholder Yield
2.3%
Dividend + buyback return per year
Buyback Yield
2.3%
Dividend Yield
—
Payout Ratio
—
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.00
Growth Streak
Consecutive years of dividend increases
0Y
3Y Div CAGR
0.0%
5Y Div CAGR
0.0%
Ex-Dividend Date
—
Payment Cadence
Semi-Annual
0 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$290M
Estimated Shares Retired
4M
Approx. Share Reduction
2.3%
Shares Outstanding
Current diluted share count from the screening snapshot
195M
At 2.3%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2023 | $0.01 | 0.0% | 0.0% | 0.0% |
| 2022 | $0.01 | 0.0% | 0.6% | 0.6% |
| 2021 | $0.01 | 0.0% | 0.1% | 0.1% |
| 2020 | $0.01 | 0.0% | 0.3% | 0.3% |
| 2019 | $0.01 | 0.0% | 1.1% | 1.1% |
FAQ
7 questionsCOO Investor Questions
Common questions answered from live analyst data and company financials.
01Is The Cooper Companies, Inc. (COO) stock a buy or sell in 2026?
The Cooper Companies, Inc. (COO) is rated Buy by Wall Street analysts as of 2026. Of 25 analysts covering the stock, 16 rate it Buy or Strong Buy, 8 rate it Hold, and 1 rate it Sell or Strong Sell. The consensus 12-month price target is $80, implying +21.9% from the current price of $66. The bear case scenario is $59 and the bull case is $124.
02What is the COO stock price target for 2026?
The Wall Street consensus price target for COO is $80 based on 25 analyst estimates. The high-end target is $98 (+48.7% from today), and the low-end target is $61 (-7.4%). The base case model target is $94.
03Is The Cooper Companies, Inc. (COO) stock overvalued in 2026?
COO trades at 14.2x times forward earnings. The stock trades at a notable premium to the broad market, which is typical for businesses with strong free cash flow and above-average growth expectations. Based on current multiples versus the peer group, the relative model signals slightly expensive versus peers. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for The Cooper Companies, Inc. (COO) stock in 2026?
The primary risks for COO in 2026 are: (1) Business segment focus — The company operates in specialized medical device segments (CooperVision and CooperSurgical), which may face sector-specific risks. (2) Leadership uncertainty — The resignation of Antalpha Platform Holding's CEO and COO created negative sentiment, potentially leading to a sell-off of COO shares. (3) Market sentiment — No major earnings surprises or regulatory actions emerged, but incremental catalysts drove stock movement. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is The Cooper Companies, Inc.'s revenue and earnings forecast?
Analyst consensus estimates COO will report consensus revenue of $4.5B (+6.7% year-over-year) and EPS of $2.35 (+94.3% year-over-year) for the upcoming fiscal year. The following year, analysts project $4.7B in revenue.
06When does The Cooper Companies, Inc. (COO) report its next earnings?
A confirmed upcoming earnings date for COO is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
07How much free cash flow does The Cooper Companies, Inc. generate?
The Cooper Companies, Inc. (COO) generated $570M in free cash flow over the trailing twelve months — a free cash flow margin of 13.5%. COO returns capital to shareholders through and share repurchases ($290M TTM).